(405 ILCS 5/2-107.2) (from Ch. 91 1/2, par. 2-107.2)
Sec. 2-107.2. Review; notice.
(a) Whenever any recipient, who is receiving treatment in a
residential mental health facility, has been receiving psychotropic medication or electroconvulsive therapy in that facility continuously or on a regular basis for a
period of 3 months, and, if the treatment is continued while
the recipient
is a resident in that facility, every 6 months
thereafter, for so long as the treatment shall continue, the
facility
director shall convene a treatment review panel to review the treatment.
(b) At least 7 days prior to the date of the meeting, the recipient, his
or her guardian, if any, and the person designated under subsection (b) of
Section 2-200 shall be given written notification of the time and place of the
treatment review meeting. The notice shall also advise the recipient of his or
her right to designate some person to attend the meeting and assist the
recipient.
(c) If, during the course of the review, the recipient or guardian, if
any, advises the committee that
he no longer agrees to continue receiving the treatment,
the treatment must be
discontinued except that the treatment may be administered
under either
Section 2-107 or 2-107.1. If the recipient and guardian, if any, continues
to agree to the treatment, the treatment
shall be continued if the
committee determines that the recipient is receiving appropriate treatment and that the benefit to the recipient outweighs any risk of harm
to the
recipient.
(d) The Department shall issue rules to implement the requirements of this
Section.
(Source: P.A. 95-172, eff. 8-14-07.)
|